In response to the Commission’s public consultation on the Critical Medicines Act, the International Association of Mutual Benefit Societies (AIM) has submitted its feedback. AIM welcomes the potential implementation of a Critical Medicines Act as a crucial step toward ensuring equitable access to medicines across Member States. While innovation is important, the Act should primarily focus on addressing shortages, which mainly affect off-patent medicines. AIM strongly supports measures that enhance affordability and availability while ensuring the sustainability of solidarity-based healthcare systems.